Physiologically‐based pharmacokinetic modeling of prominent oral contraceptive agents and applications in drug–drug interactions
Abstract Considerable interest remains across the pharmaceutical industry and regulatory landscape in capabilities to model oral contraceptives (OCs), whether combined (COCs) with ethinyl estradiol (EE) or progestin‐only pill. Acceptance of COC drug–drug interaction (DDI) assessment using physiologi...
Main Authors: | Gareth J. Lewis, Deepak Ahire, Kunal S. Taskar |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2024-04-01
|
Series: | CPT: Pharmacometrics & Systems Pharmacology |
Online Access: | https://doi.org/10.1002/psp4.13101 |
Similar Items
-
Robust physiologically based pharmacokinetic model of rifampicin for predicting drug–drug interactions via P‐glycoprotein induction and inhibition in the intestine, liver, and kidney
by: Ryuta Asaumi, et al.
Published: (2022-07-01) -
Physiologically based pharmacokinetic modeling for development and applications of a virtual celiac disease population using felodipine as a model drug
by: Farzaneh Salem, et al.
Published: (2023-06-01) -
Physiologically‐based pharmacokinetic model of sparsentan to evaluate drug–drug interaction potential
by: Nikunjkumar K. Patel, et al.
Published: (2024-02-01) -
Comprehensive Physiologically Based Pharmacokinetic Model to Assess Drug–Drug Interactions of Phenytoin
by: Leyanis Rodriguez-Vera, et al.
Published: (2023-10-01) -
Application of physiologically‐based pharmacokinetic model approach to predict pharmacokinetics and drug–drug interaction of rivaroxaban: A case study of rivaroxaban and carbamazepine
by: Lien Thi Ngo, et al.
Published: (2022-11-01)